LifeMD Inc (LFMD) Stock Analysis

Verdict: HOLD

Aggressive GLP-1 expansion and 85% gross margins drive a recovery narrative, but massive earnings misses and thin liquidity remain risks.

Investment score: 64/100

Analysis as of 2026-07-07

Is LifeMD Inc stock worth reviewing? The TradeMates thesis

LFMD is a high-risk, high-reward telehealth play. The model favors the stock due to its industry-leading gross margins and strong technical momentum, despite a history of earnings misses.

7-factor investment score

Valuation: 55/100 (weight 20%)
Financial Health: 50/100 (weight 15%)
Technical Momentum: 80/100 (weight 15%)
Earnings Quality: 35/100 (weight 15%)
Insider Sentiment: 45/100 (weight 10%)
Analyst Consensus: 90/100 (weight 10%)
Risk-Adjusted Return: 65/100 (weight 15%)

LifeMD Inc opportunities and risks

What speaks for LFMD

GLP-1 Growth Vector

What speaks against LFMD

Persistent Earnings Volatility

Peers and competitors

CTEV
MDRX
TBRG
SLP
HCAT

Trailing-twelve-month ratios
Ticker	P/E	P/S	EV/EBITDA	Gross margin	Net margin	FCF yield
LFMD	n/a	1.1x	n/a	85.9%	-7.4%	6.2%
CTEV	n/a	0.6x	9.9x	61.1%	-29.3%	-6.4%
MDRX	n/a	1.5x	11.0x	52.5%	-14.7%	9.6%
TBRG	89.3x	1.1x	16.2x	51.2%	1.3%	10.7%
SLP	n/a	4.6x	19.9x	62.0%	-78.0%	6.2%
HCAT	n/a	0.6x	n/a	46.0%	-87.7%	5.4%
Peer median	n/a	1.1x	11.0x	52.5%	-29.3%	6.2%

Frequently asked questions about LifeMD Inc (LFMD)

Is LFMD stock a good investment?

The TradeMates model rates LifeMD Inc as HOLD with an investment score of 64/100. LFMD is a high-risk, high-reward telehealth play. The model favors the stock due to its industry-leading gross margins and strong technical momentum, despite a history of earnings misses. This is algorithmic model output, not personal investment advice.

Is LFMD stock a buy?

The TradeMates model verdict for LFMD is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.